Literature DB >> 22214145

The use of osteo-conductive stem-cells allograft in lumbar interbody fusion procedures: an alternative to recombinant human bone morphogenetic protein.

Eubulus J Kerr1, Ajay Jawahar, Terry Wooten, Stephen Kay, David A Cavanaugh, Pierce D Nunley.   

Abstract

UNLABELLED: The use of autogenous bone graft in spinal fusion is progressively declining. Different allografts including the human bone morphogenetic protein have been proposed to facilitate fusion rates but are associated with various adverse effects. Osteocel belongs to a new class of allograft tissue material that is a re-absorbable biomaterial with allogenic mesenchymal stem cells. The purpose of the present retrospective study was to analyze the clinical effectiveness of mesenchymal stem cells allograft (Osteocel") to achieve radiological arthrodesis in adult patients undergoing lumbar interbody fusion surgery for different indications. Fifty-two consecutive patients received lumbar interbody fusion at one (69%) or two contiguous (31%) levels of lumbar spine for various indications. The mean age was 50 (range, 27 to 77) years; 60% were females; 43% were habitual smokers and 21% had previously failed surgery at the index level(s). OUTCOME MEASURES: Radiographic analyses of fusion by plain films and CT scans. Procedures performed were circumferential fusion (67%), ALIF (17%) and TLIF (16%). Followup radiographic data was analyzed to establish arthrodesis versus failure (pseudarthrosis), number of months until achievement of fusion, and possible factors affecting the fusion rate. Followup ranged from 8 to 27 (median, 14) months. Solid arthrodesis was achieved in 92.3% of patients at median followup time of 5 months (95% Cl; range, 3 to 11 months). Kaplan-Meier survival curves and Mantle-Cox test were conducted to assess the effect of various factors on the rate of fusion. Statistics showed that increasing age (older than 50 years) (p = 0.017) and habitual smoking (p = 0.015) delayed the fusion time and increased the risk of pseudarthrosis. The use of Osteocel allograft is safe and effective in adult patients undergoing lumbar interbody spinal fusion procedure. Increased age and habitual smoking delays fusion but gender, previous surgery at the index level, type of procedure and number of levels do not affect the fusion rates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22214145

Source DB:  PubMed          Journal:  J Surg Orthop Adv        ISSN: 1548-825X


  22 in total

1.  Current concepts on spinal arthrodesis in degenerative disorders of the lumbar spine.

Authors:  Marios G Lykissas; Alexander Aichmair
Journal:  World J Clin Cases       Date:  2013-04-16       Impact factor: 1.337

2.  Mesenchymal stem cells derived from vertebrae (vMSCs) show best biological properties.

Authors:  Giovanni Barbanti Brodano; Silvia Terzi; Luisa Trombi; Cristiana Griffoni; Mauro Valtieri; Stefano Boriani; Maria Cristina Magli
Journal:  Eur Spine J       Date:  2013-09-24       Impact factor: 3.134

3.  Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.

Authors:  Abhijeet Kadam; Paul W Millhouse; Christopher K Kepler; Kris E Radcliff; Michael G Fehlings; Michael E Janssen; Rick C Sasso; James J Benedict; Alexander R Vaccaro
Journal:  Int J Spine Surg       Date:  2016-09-22

4.  Human mesenchymal stem cells and biomaterials interaction: a promising synergy to improve spine fusion.

Authors:  G Barbanti Brodano; E Mazzoni; M Tognon; C Griffoni; M Manfrini
Journal:  Eur Spine J       Date:  2012-03-16       Impact factor: 3.134

Review 5.  Bone repair with skeletal stem cells: rationale, progress to date and clinical application.

Authors:  Elena A Jones; Peter V Giannoudis; Dimitrios Kouroupis
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-01       Impact factor: 5.346

Review 6.  The role of stem cell therapies in degenerative lumbar spine disease: a review.

Authors:  David Oehme; Tony Goldschlager; Jeffrey V Rosenfeld; Peter Ghosh; Graham Jenkin
Journal:  Neurosurg Rev       Date:  2015-03-07       Impact factor: 3.042

7.  Multipotential stromal cell abundance in cellular bone allograft: comparison with fresh age-matched iliac crest bone and bone marrow aspirate.

Authors:  Thomas G Baboolal; Sally A Boxall; Yasser M El-Sherbiny; Timothy A Moseley; Richard J Cuthbert; Peter V Giannoudis; Dennis McGonagle; Elena Jones
Journal:  Regen Med       Date:  2014-03-12       Impact factor: 3.806

Review 8.  Cellular bone matrices: viable stem cell-containing bone graft substitutes.

Authors:  Branko Skovrlj; Javier Z Guzman; Motasem Al Maaieh; Samuel K Cho; James C Iatridis; Sheeraz A Qureshi
Journal:  Spine J       Date:  2014-06-11       Impact factor: 4.166

9.  Lineage mapping and characterization of the native progenitor population in cellular allograft.

Authors:  Mike Chen; Rahul Jandial; Josh Neman; Vincent Duenas; Claudia Kowolik; Amanda Hambrecht
Journal:  Spine J       Date:  2013-01-08       Impact factor: 4.166

10.  Predictive Factors and Rates of Fusion in Minimally Invasive Transforaminal Lumbar Interbody Fusion Utilizing rhBMP-2 or Mesenchymal Stem Cells.

Authors:  Samuel C Overley; Steven J McAnany; Muhammad A Anwar; Robert K Merrill; Andrew Lovy; Javier Z Guzman; Sergey Zhadanov; Amish Doshi; Edward Rothenberg; Avani Vaishnav; Catherine Gang; Sheeraz A Qureshi
Journal:  Int J Spine Surg       Date:  2019-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.